Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06469151 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT06469151 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 84 participants.
The verdict
NCT06469151, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to measure safety, tolerability, and pharmacokinetics (PK) of a single dose of AZD5148 administered via intravenous (IV) bolus or intramuscular (IM) injection in healthy participants
Interventions
- DRUG Placebo
- DRUG AZD5148
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2025-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06469151
The ClinicalTrials.gov registry entry for NCT06469151 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06469151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06469151 about?
NCT06469151 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults". The purpose of this study is to measure safety, tolerability, and pharmacokinetics (PK) of a single dose of AZD5148 administered via intravenous (IV) bolus or intramuscular (IM) injection in healthy participants
What is the current status of trial NCT06469151?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2024-06-24. Estimated completion is 2025-10-22.
What interventions are being tested in trial NCT06469151?
The interventions under investigation include: Placebo (DRUG), AZD5148 (DRUG).
Who is sponsoring clinical trial NCT06469151?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.